Kusajili – Clinical trials directory

Result of your search per sponsor: FoldRx Pharmaceuticals, a Pfizer Company

Woman and Man Max 99 years
FoldRx Pharmaceuticals, a Pfizer Company Update Il y a 4 ans

A double-blind, randomized study looking at the efficacy, safety and tolerability of tafamidis meglumine (PF-06291826) 20 mg or 80 mg compared to placebo when taken daily by oral administration mouth in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM) The primary objective of this study is to assess the efficacy of an oral dose of 20 mg or 80 mg tafamidis meglumine soft-gel capsules based on all-cause mortality and on frequency of cardiovascular-re...

Country None
organs None
Specialty None

unknown

More information